Neurogenic Tumors of Mediastinum

From Medscape – Dale K Mueller, MD et al.

Background

Several tumors of neurogenic origin can occur in the mediastinum. Tumors that occur in this area of the chest can present in many different ways clinically and can produce many different pathologic processes. An understanding of the embryology of this area and of the anatomic relationships of the normal structures within the mediastinum is essential in the proper determination of the exact nature of a mass or tumor located in this area.

History of the Procedure

Although the entire field of surgery is an ancient one, successful surgical procedures within the thorax are a relatively recent advancement. Until the era when the airway and ventilation could be controlled artificially, the mediastinum, like other parts of the thorax, was deemed a dangerous area to approach.

A few surgeons in the late 1800s and early 1900s attempted and described surgical approaches to the mediastinum. In 1888, Nassiloff first showed that the esophagus was accessible using a posterior approach. In this time frame, with no ability to manage the airway or to ventilate safely, such a surgical approach had to remain completely extrapleural because perforation of the pleura would result in a fatal pneumothorax.

In 1893, Bastinelli described the removal of an anterior mediastinal dermoid cyst. The procedure required resection of the manubrium, but the patient recovered.

In 1897, Milton wrote extensively on mediastinal surgery using the median sternotomy approach. He tried this approach first on human cadavers, finding that median sternotomy gave him excellent access to the mediastinum. He then used the same approach to explore the mediastinum of a live goat. Although he did enter the pleural cavity of the animal, he was able to perform a tracheostomy and give artificial respiration through it. This support enabled him to successfully explore the mediastinum and allowed the animal to have an uneventful recovery. Milton then described a human case in which he resected most of a tuberculous sternum plus 2 large tuberculous lymph nodes from the mediastinum, successfully avoiding the pleural spaces. This patient did well.

In 1940, Heuer published a monograph on mediastinal tumors. Most of the cases referenced in it were from the 1920s and 1930s, and, in spite of Milton’s previously described work, no reference was made to the use of median sternotomy as an acceptable surgical approach to the mediastinum.

Heuer noted that at that time dermoid cysts and teratomas were the most commonly found tumors of the mediastinum. He also described successful removal of neurogenic tumors from the posterior mediastinum and described several types of thymic tumors.

In 1939, Alfred Blalock reported the first case in which symptoms of myasthenia gravis were completely relieved by removal of a thymic tumor, thus initiating a surgical option in the treatment of that disease.[1]

In 1995, video-assisted removal of neurogenic tumors was reported in combination with microneurosurgical techniques.

Recently, isolated reports of robotic resection of neurogenic tumors have also been reported.[2]

Problem

Any discussion of masses and tumors of the mediastinum requires delineation of the boundaries of that area. When defining the location of specific mediastinal masses, the portion of the thorax defined as the mediastinum extends from the posterior aspect of the sternum to the anterior surface of the vertebral bodies and includes the paravertebral sulci. The mediastinum is limited bilaterally by the mediastinal parietal pleura and extends from the diaphragm inferiorly to the level of the thoracic inlet superiorly.

Because some mediastinal tumors and other masses are most often found in particular mediastinal locations, many authors have artificially subdivided the area for better descriptive localization of specific lesions. Most commonly, the mediastinum is subdivided into 3 spaces or compartments (ie, anterior, middle, posterior) when discussing the location or origin of specific masses or neoplasms. The anterior compartment extends from the posterior surface of the sternum to the anterior surface of the pericardium and great vessels. The middle compartment, or middle mediastinum, is located between the posterior limit of the anterior compartment and the anterior longitudinal spinal ligament. The posterior mediastinum is the area posterior to the heart and trachea and includes the paravertebral sulci.

Common anterior mediastinal tumors include thymomas, lymphomas, germ cell tumors, and mesenchymal tumors. Benign conditions include goiters and lymphangiomas. Most anterior mediastinal tumors are thymomas.

While neoplasms of the middle mediastinum are most commonly of lymphatic origin, neurogenic tumors also may occasionally occur in this area. Another significant group of masses identified in this compartment is cystic structures associated with a developmental abnormality of the primitive foregut or the precursors of the pericardium or pleura.[3]

Neurogenic tumors are, by far, the most common neoplasm of the posterior mediastinum. Tumors originating from lymphatic, vascular, or mesenchymal tissues can also be found in this compartment.

Epidemiology

Frequency

A review of collected series reveals that many mediastinal neoplasms and masses vary in incidence and presentation depending on patient age. Specific types of mediastinal tumors characteristically occur in specific areas within the mediastinum.

Historically, in adults, the most common type of mediastinal tumor or cyst found is the neurogenic tumor (21%), followed by thymic tumors (19%), lymphomas (13%), and germ cell tumors (10%). Foregut and pericardial cysts are the next most frequently occurring abnormality within this group. More recent data from several large series indicate that thymomas have become the most common mediastinal tumor. Some series also indicate that mediastinal lymphoma has passed neurogenic tumors in frequency.

In children and infants, neurogenic tumors are the most commonly occurring tumor or cyst, followed by foregut cysts, germ cell tumors, lymphomas, lymphangiomas and angiomas, tumors of the thymus, and pericardial cysts.

In adults, only approximately 1-2% of neurogenic tumors are malignant. In patients younger than 20 years or older than 40 years, approximately one third of mediastinal tumors are malignant, while in patients aged 20-40 years, roughly half are malignant. Benign lesions generally occur in individuals aged 20-50 years and occur slightly more frequently in women than in men.

Approximately two thirds of mediastinal tumors and cysts are symptomatic in the pediatric population, while only approximately one third produce symptoms in adults. The higher incidence of symptoms in the pediatric population is most likely related to the fact that a mediastinal mass, even a small one, is more likely to have a compressive effect on the small, flexible airway structures of a child.

When considering all age groups, nearly 55% of patients with benign mediastinal masses are asymptomatic at presentation, compared to only approximately 15% of those in whom masses are found to be malignant.

Neurogenic tumors make up approximately 21% of all adult mediastinal tumors and 35% of all pediatric mediastinal tumors. Neurogenic tumors are the most common posterior mediastinal mass. Neurogenic tumors make up roughly 20% of all mediastinal tumors.

Almost all neurogenic tumors in adult patients are of nerve sheath origin, these being neurilemomas and neurofibromas.

Approximately 90% of pheochromocytomas occur in the adrenal medulla, and only approximately 2% of pheochromocytomas occur in the chest.

Roughly 10% of pheochromocytomas are associated with one of a variety of familial syndromes, the most noted of which are the multiple endocrine neoplasia syndromes. One interesting syndrome specifically associated with multiple extraadrenal pheochromocytomas is the Carney triad, in which these neoplasms occur in association with pulmonary hamartomas and gastric leiomyosarcomas. However, this syndrome does not appear to be familial.

Etiology

Neurogenic tumors of the mediastinum arise from cells of the nerve sheath, paraganglionic tissue, and autonomic ganglia, all of which originate embryonically from the neural crest. Several tissues, including neural tissue, neural sheath tissue, and associated fibrous connective tissue of mesodermal origin, can be the source of these neoplasms.

Pathophysiology

Tumors and cysts of the mediastinum can produce abnormal effects at both systemic and local levels.

Local pathophysiology

Because of the malleable nature and small size of the pediatric airway and other normal mediastinal structures, benign tumors and cysts can produce abnormal local effects. These effects are more evident in children than in adults. Compression or obstruction of portions of the airway, the esophagus, or the right heart and great veins by an enlarging tumor or cyst can easily occur and can result in a number of symptoms. Infection can occur primarily within some of these mediastinal lesions, particularly those of a cystic nature, or can occur secondarily in nearby structures, such as the lungs, as a result of local compression or obstruction.

Malignant mediastinal tumors can cause all of the same local effects as those associated with benign lesions but, in addition, can produce abnormalities by invasion of local structures. Local structures most commonly subject to invasion by malignant tumors include the tracheobronchial tree and lungs, esophagus, superior vena cava, pleura and chest wall, and any adjacent intrathoracic nerves. Pathophysiologic changes that can be produced by invasion of specific structures are obstructive pneumonia and hemoptysis; dysphagia; superior vena cava syndrome; pleural effusion; and various neurologic abnormalities such as vocal cord paralysis, Horner syndrome, paraplegia, diaphragmatic paralysis, and pain in the distribution of specific sensory nerves.

Systemic pathophysiology

Certain mediastinal tumors can produce systemic abnormalities. Many of these manifestations are related to bioactive substances produced by specific neoplasms.

Tumors developing from autonomic nerve cells can produce several vasoactive substances. The most common of these is neuroblastoma, which produces excess amounts of the catecholamines, epinephrine, and norepinephrine. Ganglioneuroma and ganglioneuroblastoma can produce these substances but do so less often. Autonomic nerve tumors are also capable of producing excess amounts of vasoactive intestinal peptide. Neuroblastomas are thought to produce abnormal antibodies that are responsible for some unusual neurologic manifestations in some children with the tumor.

Some neurosarcomas have been associated with the production of an insulinlike substance that, in turn, can produce hypoglycemia.

Presentation

Many mediastinal tumors and cysts produce no symptoms and are found incidentally during chest radiographs or other imaging studies of the thorax performed for another reason. Symptoms are present in approximately one third of adult patients with a mediastinal tumor or cyst but are seen more commonly in the pediatric population, in which nearly two thirds present with some symptoms. In adults, asymptomatic masses are more likely to be benign.

Symptoms associated with the respiratory tract predominate in pediatric patients because airway compression is more likely. This occurs because of the significant malleability of the airway structures and the small size of the chest cavity in infants and children. Symptoms most often observed include persistent cough, dyspnea, and stridor. If the location and size of the mass produces partial or complete obstruction, obstructive pneumonia can also occur. Infectious symptomatology, and even signs of sepsis, can occur if a mediastinal cyst becomes infected.

Constitutional symptoms, such as weight loss, fever, malaise, and vague chest pain, commonly occur with malignant tumors in pediatric patients.

Symptoms associated with compression of some portion of the respiratory tract can be produced by benign lesions in adults, but this occurs much less commonly than in children. Infectious symptoms or sepsis from infection of a mediastinal cyst can occur in adults, although this is also very unlikely in persons in this age group. However, malignant lesions are more likely to produce signs and symptoms of obstruction, compression, or both because they invade or transfix normal mediastinal structures.

Clinical findings associated with these malignant properties include cough, dyspnea, stridor, dysphagia, and even more dramatic findings such assuperior vena cava syndrome. Invasion of the chest wall or pleura by a malignant neoplasm can produce persistent pleural effusions and a significant amount of local pain. Invasion of nearby nerves within the thorax can produce local and referred pain and a variety of other findings such as hoarseness from recurrent nerve paralysis, diaphragmatic paralysis from phrenic nerve paralysis, Horner syndrome from autonomic nerve invasion, and even motor paralysis from direct spinal cord involvement. Pain in the shoulder or upper extremity can occur from invasion of the ipsilateral brachial plexus. Systemic findings such as weight loss, fever, and malaise also occur.

In von Recklinghausen disease or neurofibromatosis, an inheritable disease, the individual may develop multiple tumors, generally neurofibromas.

Functioning mediastinal pheochromocytomas produce an excess of circulating catecholamines. The hallmark clinical finding in individuals with these neoplasms is hypertension. The hypertension may be persistent, paroxysmal, or persistent with paroxysmal episodes. Hypertensive crises may occur and may be triggered or exacerbated by anesthesia, trauma, and the onset of labor. The hypertension found in these individuals may be termed malignant and most often is resistant to any standard antihypertensive therapy. It certainly may lead to the usual complications of long-standing or severe hypertension such as stroke, cardiac failure, or renal function abnormalities.

In some patients, paroxysmal episodes can be accompanied by other symptoms, which include headaches, diaphoresis, anxiety, chest pain, palpitations, and pallor. Some patients also have an associated tachycardia.

Marked vasoconstriction from the excessive catecholamine discharge associated with these neoplasms creates a severely volume-contracted state in these individuals. This, in turn, produces the appearance of an elevated hematocrit value.

Indications

Treatment selection for a given mediastinal tumor or cyst depends on the diagnosis of the lesion being investigated. Surgical resection is the primary treatment of choice in a large percentage of cases of neurogenic tumors.

Surgical resection is the treatment of choice for tumors originating from nerve sheath tissue, including neurilemoma, neurofibroma, and neurogenic sarcoma. Complete resection of the more malignant forms of these tumors may not be possible, and additional treatment modalities may be required.

Primary resection is the treatment of choice for neurogenic tumors of paraganglionic origin, which include paraganglionoma, chemodectomas, and mediastinal pheochromocytoma. Approximately 10% of pheochromocytomas are malignant and may not be entirely resectable. Some, even though benign, may be incompletely resected because of their location and increased vascularity. Preoperative treatment including alpha and beta blockade to prevent malignant hypertension during dissection is critical to excision of these tumors.

Peripheral neuroectodermal tumors (PNET), otherwise known as Askin tumors, are rare tumors occurring in the posterior sulcus or chest wall of adolescent and young adult patients. They are believed to develop from intercostal nerve tissue. Standard therapy includes en bloc resection, with accompanying radiotherapy and chemotherapy if complete resection is not possible.

Treatment varies for neurogenic tumors originating from autonomic nervous tissues. Ganglioneuroma, the most mature and benign form of autonomic nerve tumor, is treated by surgical resection. Neuroblastoma and ganglioneuroblastoma identified at an early stage of disease also may be treated with primary resection. Advanced stages of these diseases are treated primarily with chemotherapy, and surgical resection is rarely indicated.

Relevant Anatomy

When defining the location of specific mediastinal masses, the portion of the thorax defined as the mediastinum extends from the posterior aspect of the sternum to the anterior surface of the vertebral bodies and includes the paravertebral sulci. It is limited bilaterally by the mediastinal parietal pleura and extends from the diaphragm inferiorly to the level of the thoracic inlet superiorly.

Traditionally, the mediastinum is artificially subdivided into 3 compartments for better descriptive localization of specific lesions. When the location or origin of specific masses or neoplasms is discussed, the compartments or spaces are most commonly defined as anterior, middle, and posterior.

The anterior compartment extends from the posterior surface of the sternum to the anterior surface of the pericardium and great vessels. The anterior compartment normally contains the thymus gland, adipose tissue, and lymph nodes.

The middle compartment, or middle mediastinum, is located between the posterior limit of the anterior compartment and the anterior longitudinal spinal ligament. This area contains the heart, pericardium, ascending and transverse portions of the aorta, brachiocephalic vessels, main pulmonary arteries and veins, superior and inferior vena cavae, trachea and mainstem bronchi, numerous lymph nodes, and various neural structures such as the phrenic nerves. A small percentage of neurogenic tumors occur in the middle mediastinal compartment.

The posterior mediastinum is the area posterior to the heart and trachea and includes the paravertebral sulci. It contains the descending thoracic aorta and ligamentum arteriosum, esophagus, thoracic duct, azygos vein, and numerous neural structures (including autonomic ganglion and nerves, lymph nodes, and adipose tissue). Almost all tumors of neurogenic origin occupy this portion of the mediastinum.

Contraindications

Surgical removal is not indicated as primary treatment for some specific mediastinal tumors and cysts. Advanced stages of neuroblastoma and ganglioneuroblastoma are the tumors of neurogenic origin for which surgical resection is not considered as primary treatment.

Laboratory Studies

  • Serum and urinary catecholamine levels, including vanillylmandelic acid and metanephrine levels

    • Serum assays can be performed to obtain total or fractionated levels of catecholamines. Individual fractionated values can be obtained for epinephrine, norepinephrine, and dopamine.
    • Several authors note that for these levels to be accurate, the patient must be supine, euvolemic, and in a fasting state at the time the blood sample is taken. Also, blood must be drawn from an intravenous access site that has been in place for at least 30 minutes. Falsely positive vanillylmandelic acid levels are possible in patients who consume products with high vanilla content, such as coffee and tea.
    • Because numerous medications can interfere with assaying techniques and with endogenous catecholamine release, those that interfere must be carefully screened for and stopped, if necessary, to obtain an accurate result.
    • Serum and 24-hour urinary catecholamine levels should be measured in all infants and children who present with a posterior mediastinal or paravertebral mass. These levels are frequently elevated in patients with neuroblastoma and ganglioneuroblastoma.
    • In addition, appropriate clinical signs and symptoms and elevated levels of serum catecholamines and urinary vanillylmandelic acid (VMA) mandate studies to identify the presence of a pheochromocytoma. Approximately 1-2% of pheochromocytomas are located in the thorax. Elevated levels of serum and urinary catecholamines are present in approximately 90% of individuals with a functioning pheochromocytoma.
    • Serum metanephrine levels also may be measured.
  • Twenty-four–hour urinary VMA, homovanillic acid, and metanephrine levels

    • These degradation products of catecholamine metabolism can be assayed in 24-hour, 12-hour, or 2- to 3-hour urine collections. Levels may be elevated in patients undergoing an evaluation for neuroblastoma, ganglioneuroblastoma, and pheochromocytoma. These levels have been found to be elevated in 85-95% of children with neuroblastoma and in approximately 50% of those with ganglioneuroblastoma.
    • Again, urinary excretion of these substances can be altered by medications or by increased intake of foods with high levels of phenolic acids and vanillin, such as coffee and tea. Attention should be paid to these factors prior to testing to avoid invalid results.
    • Note that assays of baseline serum and urinary free catecholamine levels and urinary metanephrines and VMA levels should all be obtained when these studies are undertaken. This is advised because a small percentage of patients with pheochromocytoma may have a positive result in only one of these measured assays.
  • Serum glucose and insulin levels

    • These may be suppressed by the production of an insulinlike substance by certain tumors.
    • These include some fibrosarcomas and neurosarcomas and occasional carcinoid tumors.

Medical Therapy

While most tumors and cysts of the mediastinum are treated surgically, medical therapy is the primary form of treatment in several diseases.

Benign schwannomas and neurofibromas

Treatment for these lesions is surgical resection. This includes the plexiform varieties and melanotic schwannoma.

Granular cell tumors

Treatment for this rare lesion is surgical in nature.

Malignant schwannoma and neurofibrosarcoma

Surgical resection is the primary mode of therapy. Radiation therapy may be used postoperatively to control residual disease, but the benefit of this is unknown. No known chemotherapeutic regimens are effective against these tumors.

Ganglioneuroma

Treatment is surgical in nature.

Neuroblastoma and ganglioneuroblastoma

Treatment of mediastinal neuroblastoma is based on the evaluation of a number of risk factors that are used to assign a stage to the disease according the INSS. This is identical to the staging system used for neuroblastoma occurring elsewhere in the body. Patients at INSS stages 1 and 2 are considered candidates for resection. For patients with more advanced disease (INSS stage 3, 4, or 4S), a combination of surgery and chemotherapy is recommended. High-risk patients rarely benefit from surgery. Intense chemotherapy with whole-body irradiation or myeloablative chemotherapy is administered, followed by autologous bone marrow transplant.

Neuroblastoma occurs much less frequently in adults than in children and infants but is a much more aggressive disease. Stage 1 disease is treated surgically, while irradiation is recommended for stage 2 disease. Chemotherapy has been tried for disseminated disease in adults, although no proven benefit has been observed.

Ganglioneuroblastoma

These tumors are also graded using the INSS. Surgical resection is indicated in those with early disease, and chemotherapeutic therapy is added for those with more advanced disease.

Melanotic progonoma

Surgical resection is the only recommended treatment.

Askin tumor

Surgical resection followed by irradiation and chemotherapy is recommended in all cases. Some studies have used myeloablative chemotherapy or whole-body irradiation followed by autologous bone marrow transplant, but, to date, benefits of this aggressive therapy have not been identified.

Chemodectomas are primarily treated with surgical resection. Preoperative embolization may be indicated because of the excessive vascularity of these tumors. Radiation therapy has also been used and is an acceptable alternative to surgical resection.

Surgical Therapy

In cases of benign neoplasms, complete excision of the lesion itself is generally sufficient. Benign neurofibroma requires some resection in addition to the lesion itself, that being resection of the associated nerve. All benign neoplasms that are encapsulated should be resected without violation of the capsule. VATS resection is now commonplace for these benign tumors. Shorter hospital stay and more rapid return to work have been demonstrated with this method.

When surgical resection of malignant neoplasms of the mediastinum is the primary treatment, bloc resection of the tumor should be performed whenever possible. Regional lymphadenectomy should accompany surgical resection of operable neuroblastomas.

Preoperative Details

Standard preoperative management applicable to all chest surgical cases applies to the preoperative management of individuals undergoing resection of mediastinal tumors.

Airway management is of paramount importance when dealing with tumors that can produce a mass effect on these structures. For safe management of the airway distorted or narrowed by a mediastinal mass, consider detailed preoperative assessment of the airway and ensure adequate visualization and readily available supplementary equipment (eg, flexible bronchoscope). Placement of a double-lumen endotracheal tube to provide single-lung ventilation is usually preferred for any procedure in which a thoracotomy approach is used.

Some mediastinal tumors may require extensive resection of adjacent tissues, and blood loss may be substantial in these cases. Provide for adequate intravenous access, appropriate monitoring capability, and easy availability of necessary blood products (all of paramount importance) before surgery is begun.

Involvement of associated intrathoracic structures by tumor may mandate their resection. Pulmonary resection, excision of nervous structures (eg, phrenic, vagus, sympathetic chain), or even resection of major vascular structures (eg, superior vena cava) may be required. Importantly, the surgeon must be prepared for this and the patient must be informed preoperatively that such resection may be required because this may have an additional impact on recovery and perioperative risk.

Several mediastinal tumors can produce important effects that should be taken into account preoperatively. Neurogenic tumors that secrete catecholamines require special consideration.

Pheochromocytoma

Perform preoperative treatment on individuals with pheochromocytoma in order to prevent a catecholamine surge and an intraoperative hypertensive crisis.

Most authors recommend the administration of the alpha-blocker phenoxybenzamine. This medication is initiated approximately 2 weeks preoperatively, beginning at doses of 10 mg twice a day and increasing the dose every other day until a normotensive or near-normotensive state, with minimization or elimination of paroxysmal episodes, is achieved. Most patients require 40-120 mg/d to achieve this effect. Because of its prolonged half-life, reduction of the dose 24-48 hours before surgery is recommended, otherwise postoperative hypotension may occur after the source of excess catecholamine production is removed.

Other drugs that may be used instead are prazosin (a selective alpha-blocker) or labetalol (an alpha- and beta-blocker). Alpha-methylparatyrosine has been used successfully in a few patients who cannot tolerate alpha-blockade with other agents.

Preoperative beta-blockade can also be performed but is indicated only if persistent tachycardia or supraventricular arrhythmias are present. Beta-blockade should be started only after alpha-blockade is stabilized to prevent unopposed beta-blockade.

Atropine should not be given with preoperative medication. Anesthetic induction with good oxygenation should be rapid and unimpaired. Most commonly, thiopentone is used for induction; however, fentanyl and alfentanil can also be used because they do not result in histamine release, as do other agents. The choice of muscle relaxant is important because some (eg, tubocurarine, atracurium) can cause histamine release and others (eg, pancuronium) can release catecholamine stores. Vecuronium is the drug of choice because it produces none of these effects.

Pheochromocytomas are highly vascular tumors. Adequate availability of blood products is a key feature in the treatment of these patients.

Intraoperative Details

As with all thoracic surgery, position the patient properly for the indicated procedure. Tumors or cysts located in the anterior mediastinum are generally approached through a median sternotomy. This approach is used for tumors of the thymus. Those located in the posterior or middle mediastinum and paravertebral sulci, such as most neurogenic tumors and foregut cysts, are approached through a VATS incision or a posterolateral thoracotomy incision.

Standard single-lumen endotracheal intubation is appropriate for resections performed via the median sternotomy approach. Use of a double-lumen endotracheal tube for single-lung ventilation is preferable for those procedures performed through a thoracotomy incision and for all procedures performed using VATS.

Specific management of neurogenic tumors with intraspinal extension should be mentioned. Evaluation of all patients with tumors of the posterior mediastinum preoperatively is essential to rule out intraspinal extension. Combined management by neurosurgical and thoracic surgical teams is warranted when intraspinal extension is suggested. If intraspinal extension is first identified at the time of thoracotomy and was not considered prior to this, the outcome could prove disastrous. The approach to these tumors usually requires laminectomy for resection of the intraspinal portion of the tumor and thoracotomy for the intrathoracic portion. In cases in which laminectomy must be performed at multiple levels, some form of stabilization of the vertebral column is undertaken. Laminectomy combined with VATS and thoracoscopy have also been reported for neurogenic tumors involving the spinal column.

A consideration for the resection of pheochromocytomas is that manipulation of a pheochromocytoma during surgical resection may result in a sudden introduction of catecholamines into the circulation. This can occur even in the presence of preoperative preparation with alpha- and beta-blockers. Early in the dissection, care must be taken during surgery to manipulate these tumors as little as possible and to control venous outflow.

Postoperative Details

Care of patients after resection or biopsy of mediastinal tumors is similar to that for any noncardiac surgery of the chest.

Extubation can be performed at the completion of the case or shortly thereafter in the postanesthesia recovery area. Some patients require ventilatory support for a longer time and should be managed accordingly.

Pulmonary toilet is an essential part of postoperative management after any kind of chest surgery to prevent atelectasis and to mobilize and clear any bronchial secretions. Various methods to assist with pulmonary toilet are available.

Pain control is a critical factor in postoperative management after thoracic surgery. Adequate cough effort and ventilatory excursion cannot be maintained without satisfactory pain control. The administration of analgesic agents via a thoracic epidural catheter is an excellent and highly effective method of pain management. Lumbar or thoracic epidural catheters can also be used and, with proper choice of analgesic agents, can provide good pain relief. Patient-controlled analgesia (PCA) is another widely used method and is preferred to traditional intramuscular or intravenous administration of narcotics and other agents. PCA is not as efficient for pain control as epidural analgesia.

Continuous infusion of 0.25% bupivacaine at 4 mL/h through the ON-Q elastomeric infusion pump is a safe and effective adjunct to pain management after thoracotomy.[13] The use of the ON-Q Pain Relief System results in decreased narcotic use and lower pain scores compared with continuous epidural infusion. At some point after oral intake has begun, pain medication can be converted to oral analgesic agents.

Wound management is straightforward. Operative dressings are removed after 24 hours in most cases. Thoracic surgical incisions heal well and have an extremely low rate of dehiscence and infection.

Chest tubes are managed in the same way as those used in other forms of thoracic surgery. Most cases of mediastinal tumor or cyst resection or biopsy do not involve pulmonary or esophageal resection. Chest tubes are maintained on minus 20 cm of water-seal suction, and drainage from the tubes is measured daily. Intermittent chest radiographs are obtained and evaluated for findings of residual undrained collections, complete pulmonary expansion, lobar atelectasis and infiltrates, and other abnormalities. When drainage from the chest tubes is less than 400 mL in 24 hours, no air leak is present, and the chest radiograph shows full pulmonary expansion with no collections on the operated side, the chest tubes may be removed.

Follow-up

Patients who undergo resection of benign neoplasms or mediastinal cysts can be followed for a short time (ie, 3-6 mo) postoperatively while wound healing and progression of patient activity is being monitored.

Because of the heterogeneity and small numbers of malignant tumors found in the mediastinum, no single specific method has been described for the follow-up of patients who undergo intended curative resection of a malignant neoplasm. Optimal follow-up treatment for patients with thoracic malignancy has not been demonstrated in randomized controlled trials.[14]

Complications

Complications that occur after resection of mediastinal tumors are similar to those that can occur after any thoracic surgical procedure.

As with any thoracic surgical procedure, postoperative pulmonary complications are most common. Atelectasis is a common postoperative complication and can develop into pneumonia if not treated aggressively. Aggressive pulmonary toilet and pain management are the key factors in the prevention of these complications.

Wound infections after sternotomy or thoracotomy are rare. The chest wall has an excellent blood supply and, with few exceptions, healing occurs readily. In addition, existing intrathoracic infection is generally not a factor during resection of any of the noted mediastinal tumors, and these operations are considered clean procedures. The exception to this may be in cases of resection of some foregut cysts that may have secondary infection present.

Appropriate preoperative, intraoperative, and postoperative antibiotic coverage is warranted. Sternal dehiscence occurs very rarely after sternotomy performed for noncardiac procedures. If it occurs without the presence of infection, simple washout, debridement, and rewiring can be performed. If infection is present, perform aggressive debridement of devascularized bone and cartilage and a vigorous washout. Cases in which significant infection is present are best treated with rotation of muscle flaps, such as the pectoralis major and rectus abdominus muscles, to cover the wound.

Injury to the phrenic nerve can occur, resulting in temporary or permanent diaphragmatic paresis. This can cause the patient to have symptomatic dyspnea and atelectasis on the affected side.

Individuals with marginal pulmonary status from underlying pulmonary disease or those with neuromuscular abnormalities causing weakness of the muscles of respiration can experience significant respiratory difficulties from this complication.

Injury to a vagus nerve can also occur during surgery of the mediastinum. Usually, only one vagus nerve is injured, and the remaining intact nerve maintains parasympathetic input to the gut without symptoms. If both vagus nerves are injured, difficulties with gastric emptying may occur because the innervation to the pylorus is disrupted.

Outcome and Prognosis

Prognosis after resection of a mediastinal tumor varies widely depending on the type of lesion resected.

After resection of mediastinal cysts and benign tumors, the prognosis is generally excellent. This group of tumors includes such neoplasms as thymolipomas, benign teratomas, benign neurilemomas and neurofibromas, ganglioneuromas, benign paragangliomas, benign mesenchymal tumors (eg, fibromas, angiomas, lymphangiomas), ectopic benign thyroid tissue and tumors, and parathyroid adenomas.

Prognosis after treatment of malignant mediastinal tumors depends on the type of lesion, its biological behavior, and the extent of the disease present.

Neuroblastoma

Survival numbers in pediatric patients with neuroblastoma have been studied in depth and analyzed with reference to a number of clinical and biological prognostic factors. This analysis is beyond the scope of this text. However, intrathoracic neuroblastomas generally have a more favorable outcome than extrathoracic types. The overall survival rate for thoracic neuroblastomas is greater than 70% at 5 years and greater than 60% at 10 years.

Ganglioneuroblastoma

These tumors are generally less aggressive than neuroblastomas. They are evaluated using the same prognostic and staging criteria as neuroblastoma. Ganglioneuroblastomas have a better prognosis because a large percentage of them manifest as an asymptomatic solitary mass and can be completely resected in many cases.

Neuroblastomas and ganglioneuroblastomas are extremely rare but much more aggressive in adults. Neuroblastoma exhibits wide local and distant spread and is rapidly fatal, while ganglioneuroblastoma may, in some cases, be treated with surgical resection.

Askin or peripheral neuroectodermal tumor

These are very rare but very aggressive tumors. Survival is commonly less than 1 year, and long-term survival, even with aggressive therapy, is rare.

Malignant nerve sheath tumors

Malignant schwannomas occurring in patients with von Recklinghausen disease have a poorer prognosis than do those that occur in the absence of that disease.

The long-term survival rate after resection approaches 50% for this neoplasm; however, individuals with associated von Recklinghausen disease have a high incidence of local or distant recurrence within 2 years.

Malignant mediastinal paragangliomas and pheochromocytomas

Extraadrenal pheochromocytomas are rare but have a higher malignant potential than their adrenal counterparts. Malignancy can occur in as many as 10% of these tumors. These tumors are commonly aggressive locally, and metastases may occur even after a long disease-free period following resection.

Future and Controversies

Numerous exciting advances have been made in areas of diagnostic imaging, biologic analysis, and therapy.

Emerging diagnostic modalities such as PET scans and other radionuclide studies may be able to assist in the diagnosis of specific neoplasms and in posttherapy surveillance for recurrent disease.

Numerous biological markers have been identified for many tumors and will play a vital role in better identifying individual neoplasms so that treatment can be optimized.

Use of VATS technology has entered the armamentarium of the thoracic surgeon with respect to the treatment of numerous mediastinal diseases.[15, 8] This modality is already used commonly for biopsy of masses and lymph nodes. It has also been commonly used for resection of various mediastinal cysts, mediastinal parathyroid adenomas, and localized benign tumors of the posterior mediastinum such as ganglioneuromas.

Robotic resection has also been used for general thoracic surgical procedures, including thymectomy and extirpations of benign mediastinal masses. Its use may be limited by lack of appropriate instrumentation.[11]